2,190,029 Shares in DexCom, Inc. $DXCM Acquired by Employees Provident Fund Board

Employees Provident Fund Board bought a new position in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, Holdings Channel reports. The institutional investor bought 2,190,029 shares of the medical device company’s stock, valued at approximately $145,352,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Geode Capital Management LLC raised its stake in shares of DexCom by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock worth $727,842,000 after acquiring an additional 42,411 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of DexCom by 6.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock valued at $530,897,000 after purchasing an additional 516,526 shares in the last quarter. Norges Bank bought a new position in shares of DexCom during the 4th quarter valued at $483,356,000. Invesco Ltd. grew its holdings in shares of DexCom by 14.8% during the 4th quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock valued at $352,781,000 after purchasing an additional 686,228 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its holdings in shares of DexCom by 7.6% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock valued at $207,613,000 after purchasing an additional 220,313 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $72.47 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The company has a 50-day moving average price of $67.07 and a 200-day moving average price of $67.92. The company has a market cap of $27.96 billion, a price-to-earnings ratio of 30.97, a price-to-earnings-growth ratio of 1.13 and a beta of 1.45. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the firm earned $0.32 earnings per share. DexCom’s quarterly revenue was up 15.0% on a year-over-year basis. As a group, equities analysts anticipate that DexCom, Inc. will post 2.58 EPS for the current year.

Insiders Place Their Bets

In other news, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the sale, the director directly owned 52,852 shares in the company, valued at approximately $3,917,918.76. This trade represents a 7.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares in the company, valued at $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 46,694 shares of company stock worth $3,343,977. Insiders own 0.28% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DXCM. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a research note on Friday, May 1st. William Blair raised DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Barclays reissued an “underweight” rating and issued a $64.00 target price (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Finally, Piper Sandler restated an “overweight” rating and set a $88.00 target price (up from $75.00) on shares of DexCom in a report on Monday. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $84.83.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.